{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:02:59Z","timestamp":1791460979123,"version":"4.3.4"},"reference-count":108,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-026-03445-w","type":"journal-article","created":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T11:45:43Z","timestamp":1791459943000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Host chromatin architecture in HPV-driven cervical cancer: molecular mechanisms and therapeutic resistance"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4072-9907","authenticated-orcid":false,"given":"Katsuyoshi","family":"Kumagai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Kitahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayumi","family":"Chiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Yajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,8]]},"reference":[{"key":"3445_CR1","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1056\/NEJMra2404457","volume":"392","author":"KS Tewari","year":"2025","unstructured":"Tewari KS. Cervical cancer. N Engl J Med. 2025;392:56\u201371. https:\/\/doi.org\/10.1056\/NEJMra2404457.","journal-title":"N Engl J Med"},{"key":"3445_CR2","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/s41571-024-00977-w","volume":"22","author":"AA Francoeur","year":"2025","unstructured":"Francoeur AA, et al. Treatment advances across the cervical cancer spectrum. Nat Rev Clin Oncol. 2025;22:182\u201399. https:\/\/doi.org\/10.1038\/s41571-024-00977-w.","journal-title":"Nat Rev Clin Oncol"},{"key":"3445_CR3","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/S0140-6736(24)00317-9","volume":"403","author":"D Lorusso","year":"2024","unstructured":"Lorusso D, et al. Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11\/GOG-3047\/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial. Lancet. 2024;403:1341\u201350. https:\/\/doi.org\/10.1016\/S0140-6736(24)00317-9.","journal-title":"Lancet"},{"key":"3445_CR4","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1016\/S0140-6736(24)01808-7","volume":"404","author":"D Lorusso","year":"2024","unstructured":"Lorusso D, et al. Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11\/GOG-3047\/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2024;404:1321\u201332. https:\/\/doi.org\/10.1016\/S0140-6736(24)01808-7.","journal-title":"Lancet"},{"key":"3445_CR5","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1016\/S0140-6736(24)01438-7","volume":"404","author":"M McCormack","year":"2024","unstructured":"McCormack M, et al. Short-course induction chemotherapy followed by chemoradiotherapy in locally advanced cervical cancer: an international, multicentre, randomised phase 3 trial. Lancet. 2024;404:1525\u201335. https:\/\/doi.org\/10.1016\/S0140-6736(24)01438-7.","journal-title":"Lancet"},{"key":"3445_CR6","doi-asserted-by":"publisher","first-page":"e39957","DOI":"10.1097\/MD.0000000000039957","volume":"103","author":"N Shao","year":"2024","unstructured":"Shao N. Research progress on human papillomavirus-negative cervical cancer: a review. Med (Baltim). 2024;103:e39957. https:\/\/doi.org\/10.1097\/MD.0000000000039957.","journal-title":"Med (Baltim)"},{"key":"3445_CR7","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.1017\/pcm.2023.23","volume":"2","author":"B Tomasik","year":"2023","unstructured":"Tomasik B, et al. Heterogeneity in precision oncology. Camb Prisms Precis Med. 2023;2:e2. https:\/\/doi.org\/10.1017\/pcm.2023.23.","journal-title":"Camb Prisms Precis Med"},{"key":"3445_CR8","doi-asserted-by":"publisher","first-page":"102340","DOI":"10.1016\/j.ctrv.2022.102340","volume":"104","author":"S Crucitta","year":"2022","unstructured":"Crucitta S, et al. Treatment-driven tumour heterogeneity and drug resistance: lessons from solid tumours. Cancer Treat Rev. 2022;104:102340. https:\/\/doi.org\/10.1016\/j.ctrv.2022.102340.","journal-title":"Cancer Treat Rev"},{"key":"3445_CR9","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/s42003-025-09310-2","volume":"9","author":"Y Wu","year":"2025","unstructured":"Wu Y, et al. Single-cell and spatial transcriptomic profiling reveals distinct tumor microenvironment dynamics in cervical adenocarcinoma and squamous cell carcinoma. Commun Biol. 2025;9:46. https:\/\/doi.org\/10.1038\/s42003-025-09310-2.","journal-title":"Commun Biol"},{"key":"3445_CR10","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1042\/BST20253041","volume":"53","author":"DI Obanya","year":"2025","unstructured":"Obanya DI, et al. Advances in understanding the mechanisms of the human papillomavirus oncoproteins. Biochem Soc Trans. 2025;53:565\u201377. https:\/\/doi.org\/10.1042\/BST20253041.","journal-title":"Biochem Soc Trans"},{"key":"3445_CR11","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/j.cell.2017.08.028","volume":"170","author":"ER Kastenhuber","year":"2017","unstructured":"Kastenhuber ER, Lowe SW. Putting p53 in context. Cell. 2017;170:1062\u201378. https:\/\/doi.org\/10.1016\/j.cell.2017.08.028.","journal-title":"Cell"},{"key":"3445_CR12","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/s41580-019-0110-x","volume":"20","author":"A Hafner","year":"2019","unstructured":"Hafner A, et al. The multiple mechanisms that regulate p53 activity and cell fate. Nat Rev Mol Cell Biol. 2019;20:199\u2013210. https:\/\/doi.org\/10.1038\/s41580-019-0110-x.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3445_CR13","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/s41568-019-0143-7","volume":"19","author":"LN Kent","year":"2019","unstructured":"Kent LN, Leone G. The broken cycle: E2F dysfunction in cancer. Nat Rev Cancer. 2019;19:326\u201338. https:\/\/doi.org\/10.1038\/s41568-019-0143-7.","journal-title":"Nat Rev Cancer"},{"key":"3445_CR14","doi-asserted-by":"publisher","first-page":"16086","DOI":"10.1038\/nrdp.2016.86","volume":"2","author":"M Schiffman","year":"2016","unstructured":"Schiffman M, et al. Carcinogenic human papillomavirus infection. Nat Rev Dis Primers. 2016;2:16086. https:\/\/doi.org\/10.1038\/nrdp.2016.86.","journal-title":"Nat Rev Dis Primers"},{"key":"3445_CR15","doi-asserted-by":"publisher","first-page":"560","DOI":"10.3390\/genes15050560","volume":"15","author":"A Fudulu","year":"2024","unstructured":"Fudulu A, et al. Exploring the role of E6 and E7 oncoproteins in cervical oncogenesis through MBD2\/3-NuRD complex chromatin remodeling. Genes (Basel). 2024;15:560. https:\/\/doi.org\/10.3390\/genes15050560.","journal-title":"Genes (Basel)"},{"key":"3445_CR16","doi-asserted-by":"publisher","first-page":"eaal2380","DOI":"10.1126\/science.aal2380","volume":"357","author":"WA Flavahan","year":"2017","unstructured":"Flavahan WA, et al. Epigenetic plasticity and the hallmarks of cancer. Science. 2017;357:eaal2380. https:\/\/doi.org\/10.1126\/science.aal2380.","journal-title":"Science"},{"key":"3445_CR17","doi-asserted-by":"publisher","first-page":"eaaw3835","DOI":"10.1126\/science.aaw3835","volume":"379","author":"AP Feinberg","year":"2023","unstructured":"Feinberg AP, Levchenko A. Epigenetics as a mediator of plasticity in cancer. Science. 2023;379:eaaw3835. https:\/\/doi.org\/10.1126\/science.aaw3835.","journal-title":"Science"},{"key":"3445_CR18","doi-asserted-by":"publisher","first-page":"429","DOI":"10.5483\/BMBRep.2022.55.9.042","volume":"55","author":"JE Lee","year":"2022","unstructured":"Lee JE, et al. Untold story of human cervical cancers: HPV-negative cervical cancer. BMB Rep. 2022;55:429\u201338. https:\/\/doi.org\/10.5483\/BMBRep.2022.55.9.042.","journal-title":"BMB Rep"},{"key":"3445_CR19","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/nature22794","volume":"546","author":"SM Shaffer","year":"2017","unstructured":"Shaffer SM, et al. Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance. Nature. 2017;546:431\u20135. https:\/\/doi.org\/10.1038\/nature22794.","journal-title":"Nature"},{"key":"3445_CR20","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1038\/s41568-020-00302-2","volume":"20","author":"JC Marine","year":"2020","unstructured":"Marine JC, et al. Non-genetic mechanisms of therapeutic resistance in cancer. Nat Rev Cancer. 2020;20:743\u201356. https:\/\/doi.org\/10.1038\/s41568-020-00302-2.","journal-title":"Nat Rev Cancer"},{"key":"3445_CR21","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1002\/1878-0261.13559","volume":"18","author":"AK Singh","year":"2024","unstructured":"Singh AK, et al. Cis-regulatory effect of HPV integration is constrained by host chromatin architecture in cervical cancers. Mol Oncol. 2024;18:1189\u2013208. https:\/\/doi.org\/10.1002\/1878-0261.13559.","journal-title":"Mol Oncol"},{"key":"3445_CR22","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3892\/ijmm.2024.5374","volume":"53","author":"M Lizano","year":"2024","unstructured":"Lizano M, et al. Promising predictive molecular biomarkers for cervical cancer (Review). Int J Mol Med. 2024;53:50. https:\/\/doi.org\/10.3892\/ijmm.2024.5374.","journal-title":"Int J Mol Med"},{"key":"3445_CR23","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1016\/j.cell.2016.02.007","volume":"164","author":"J Dekker","year":"2016","unstructured":"Dekker J, Mirny L. The 3D genome as moderator of chromosomal communication. Cell. 2016;164:1110\u201321. https:\/\/doi.org\/10.1016\/j.cell.2016.02.007.","journal-title":"Cell"},{"key":"3445_CR24","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/s41576-018-0060-8","volume":"19","author":"MJ Rowley","year":"2018","unstructured":"Rowley MJ, Corces VG. Organizational principles of 3D genome architecture. Nat Rev Genet. 2018;19:789\u2013800. https:\/\/doi.org\/10.1038\/s41576-018-0060-8.","journal-title":"Nat Rev Genet"},{"key":"3445_CR25","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/j.cell.2015.04.004","volume":"161","author":"DG Lupi\u00e1\u00f1ez","year":"2015","unstructured":"Lupi\u00e1\u00f1ez DG, et al. Disruptions of topological chromatin domains cause pathogenic rewiring of gene-enhancer interactions. Cell. 2015;161:1012\u201325. https:\/\/doi.org\/10.1016\/j.cell.2015.04.004.","journal-title":"Cell"},{"key":"3445_CR26","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1126\/science.aad9024","volume":"351","author":"D Hnisz","year":"2016","unstructured":"Hnisz D, et al. Activation of proto-oncogenes by disruption of chromosome neighborhoods. Science. 2016;351:1454\u20138. https:\/\/doi.org\/10.1126\/science.aad9024.","journal-title":"Science"},{"key":"3445_CR27","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/s41588-019-0564-y","volume":"52","author":"KC Akdemir","year":"2020","unstructured":"Akdemir KC, et al. Disruption of chromatin folding domains by somatic genomic rearrangements in human cancer. Nat Genet. 2020;52:294\u2013305. https:\/\/doi.org\/10.1038\/s41588-019-0564-y.","journal-title":"Nat Genet"},{"key":"3445_CR28","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1038\/nature11082","volume":"485","author":"JR Dixon","year":"2012","unstructured":"Dixon JR, et al. Topological domains in mammalian genomes identified by analysis of chromatin interactions. Nature. 2012;485:376\u201380. https:\/\/doi.org\/10.1038\/nature11082.","journal-title":"Nature"},{"key":"3445_CR29","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/s41576-019-0128-0","volume":"20","author":"S Schoenfelder","year":"2019","unstructured":"Schoenfelder S, Fraser P. Long-range enhancer-promoter contacts in gene expression control. Nat Rev Genet. 2019;20:437\u201355. https:\/\/doi.org\/10.1038\/s41576-019-0128-0.","journal-title":"Nat Rev Genet"},{"key":"3445_CR30","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/j.cell.2017.05.004","volume":"169","author":"EP Nora","year":"2017","unstructured":"Nora EP, et al. Targeted degradation of CTCF decouples local insulation of chromosome domains from genomic compartmentalization. Cell. 2017; 169:930\u201344.e22. https:\/\/doi.org\/10.1016\/j.cell.2017.05.004","journal-title":"Cell"},{"key":"3445_CR31","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1016\/j.celrep.2016.04.085","volume":"15","author":"G Fudenberg","year":"2016","unstructured":"Fudenberg G, et al. Formation of chromosomal domains by loop extrusion. Cell Rep. 2016;15:2038\u201349. https:\/\/doi.org\/10.1016\/j.celrep.2016.04.085.","journal-title":"Cell Rep"},{"key":"3445_CR32","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1038\/s41588-025-02188-0","volume":"57","author":"KE Yost","year":"2025","unstructured":"Yost KE, et al. Three-dimensional genome landscape of primary human cancers. Nat Genet. 2025;57:1189\u2013200. https:\/\/doi.org\/10.1038\/s41588-025-02188-0.","journal-title":"Nat Genet"},{"key":"3445_CR33","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1101\/gr.279041.124","volume":"35","author":"VL Porter","year":"2025","unstructured":"Porter VL, et al. Rearrangements of viral and human genomes at human papillomavirus integration events and their allele-specific impacts on cancer genome regulation. Genome Res. 2025;35:653\u201370. https:\/\/doi.org\/10.1101\/gr.279041.124.","journal-title":"Genome Res"},{"key":"3445_CR34","doi-asserted-by":"publisher","unstructured":"Gu M et al. Epigenetic regulation in cancer. MedComm (2020). 2024;5:e495. https:\/\/doi.org\/10.1002\/mco2.495","DOI":"10.1002\/mco2.495"},{"key":"3445_CR35","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.trecan.2025.02.001","volume":"11","author":"TS Wilson","year":"2025","unstructured":"Wilson TS, Scaffidi P. Compromised epigenetic robustness in cancer: fueling evolution, exposing weakness. Trends Cancer. 2025;11:575\u201390. https:\/\/doi.org\/10.1016\/j.trecan.2025.02.001.","journal-title":"Trends Cancer"},{"key":"3445_CR36","doi-asserted-by":"publisher","first-page":"1633283","DOI":"10.3389\/fmicb.2025.1633283","volume":"16","author":"S Sisodiya","year":"2025","unstructured":"Sisodiya S, et al. Human papillomavirus-mediated cervical cancer: epigenetic interplay and clinical implications. Front Microbiol. 2025;16:1633283. https:\/\/doi.org\/10.3389\/fmicb.2025.1633283.","journal-title":"Front Microbiol"},{"key":"3445_CR37","doi-asserted-by":"publisher","first-page":"1617198","DOI":"10.3389\/fcimb.2025.1617198","volume":"15","author":"J Bautista","year":"2025","unstructured":"Bautista J, et al. Oncogenic viruses rewire the epigenome in human cancer. Front Cell Infect Microbiol. 2025;15:1617198. https:\/\/doi.org\/10.3389\/fcimb.2025.1617198.","journal-title":"Front Cell Infect Microbiol"},{"key":"3445_CR38","doi-asserted-by":"publisher","first-page":"9214","DOI":"10.3390\/ijms26189214","volume":"26","author":"J Li","year":"2025","unstructured":"Li J, Li S. From viral infection to genome reshaping: the triggering role of HPV integration in cervical cancer. Int J Mol Sci. 2025;26:9214. https:\/\/doi.org\/10.3390\/ijms26189214.","journal-title":"Int J Mol Sci"},{"key":"3445_CR39","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1016\/j.cell.2014.11.021","volume":"159","author":"SSP Rao","year":"2014","unstructured":"Rao SSP, et al. A 3D map of the human genome at kilobase resolution reveals principles of chromatin looping. Cell. 2014;159:1665\u201380. https:\/\/doi.org\/10.1016\/j.cell.2014.11.021.","journal-title":"Cell"},{"key":"3445_CR40","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/s41586-025-08638-3","volume":"640","author":"H Zhao","year":"2025","unstructured":"Zhao H, et al. Extensive mutual influences of SMC complexes shape 3D genome folding. Nature. 2025;640:543\u201353. https:\/\/doi.org\/10.1038\/s41586-025-08638-3.","journal-title":"Nature"},{"key":"3445_CR41","doi-asserted-by":"publisher","first-page":"100778","DOI":"10.1016\/j.xgen.2025.100778","volume":"5","author":"SJD Tjalsma","year":"2025","unstructured":"Tjalsma SJD, et al. Long-range enhancer-controlled genes are hypersensitive to regulatory factor perturbations. Cell Genom. 2025;5:100778. https:\/\/doi.org\/10.1016\/j.xgen.2025.100778.","journal-title":"Cell Genom"},{"key":"3445_CR42","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1126\/science.aag2445","volume":"354","author":"CP Fulco","year":"2016","unstructured":"Fulco CP, et al. Systematic mapping of functional enhancer-promoter connections with CRISPR interference. Science. 2016;354:769\u201373. https:\/\/doi.org\/10.1126\/science.aag2445.","journal-title":"Science"},{"key":"3445_CR43","doi-asserted-by":"publisher","first-page":"1303862","DOI":"10.3389\/fcell.2023.1303862","volume":"11","author":"G Della Chiara","year":"2023","unstructured":"Della Chiara G, et al. Enhancers dysfunction in the 3D genome of cancer cells. Front Cell Dev Biol. 2023;11:1303862. https:\/\/doi.org\/10.3389\/fcell.2023.1303862.","journal-title":"Front Cell Dev Biol"},{"key":"3445_CR44","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1128\/JCM.44.5.1755-1762.2006","volume":"44","author":"H Arias-Pulido","year":"2006","unstructured":"Arias-Pulido H, et al. Human papillomavirus type 16 integration in cervical carcinoma in situ and in invasive cervical cancer. J Clin Microbiol. 2006;44:1755\u201362. https:\/\/doi.org\/10.1128\/JCM.44.5.1755-1762.2006.","journal-title":"J Clin Microbiol"},{"key":"3445_CR45","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1046\/j.1525-1438.2001.01063.x","volume":"11","author":"CD Golijow","year":"2001","unstructured":"Golijow CD, et al. c-myc gene amplification detected in preinvasive intraepithelial cervical lesions. Int J Gynecol Cancer. 2001;11:462\u20135. https:\/\/doi.org\/10.1046\/j.1525-1438.2001.01063.x.","journal-title":"Int J Gynecol Cancer"},{"key":"3445_CR46","doi-asserted-by":"publisher","first-page":"216809","DOI":"10.1016\/j.canlet.2024.216809","volume":"588","author":"C Cao","year":"2024","unstructured":"Cao C, et al. Three-dimensional chromatin analysis reveals Sp1 as a mediator to program and reprogram HPV-host epigenetic architecture in cervical cancer. Cancer Lett. 2024;588:216809. https:\/\/doi.org\/10.1016\/j.canlet.2024.216809.","journal-title":"Cancer Lett"},{"key":"3445_CR47","doi-asserted-by":"publisher","first-page":"9423","DOI":"10.3390\/ijms26199423","volume":"26","author":"E Ladoukakis","year":"2025","unstructured":"Ladoukakis E, et al. Epigenetic biomarkers for cervical cancer progression: a scoping review. Int J Mol Sci. 2025;26:9423. https:\/\/doi.org\/10.3390\/ijms26199423.","journal-title":"Int J Mol Sci"},{"key":"3445_CR48","doi-asserted-by":"publisher","first-page":"131","DOI":"10.3892\/or.2025.8964","volume":"54","author":"X Li","year":"2025","unstructured":"Li X, et al. Histone modifications in cervical cancer: epigenetic mechanisms, functions and clinical implications (Review). Oncol Rep. 2025;54:131. https:\/\/doi.org\/10.3892\/or.2025.8964.","journal-title":"Oncol Rep"},{"key":"3445_CR49","doi-asserted-by":"publisher","first-page":"3695","DOI":"10.1038\/s41388-021-01787-5","volume":"40","author":"K Kumagai","year":"2021","unstructured":"Kumagai K, et al. WAPL induces cervical intraepithelial neoplasia modulated with estrogen signaling without HPV E6\/E7. Oncogene. 2021;40:3695\u2013706. https:\/\/doi.org\/10.1038\/s41388-021-01787-5.","journal-title":"Oncogene"},{"key":"3445_CR50","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.cell.2017.04.026","volume":"169","author":"JHI Haarhuis","year":"2017","unstructured":"Haarhuis JHI, et al. The cohesin release factor WAPL restricts chromatin loop extension. Cell. 2017;169:693\u2013707.e14. https:\/\/doi.org\/10.1016\/j.cell.2017.04.026","journal-title":"Cell"},{"key":"3445_CR51","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.cell.2017.09.026","volume":"171","author":"SSP Rao","year":"2017","unstructured":"Rao SSP, et al. Cohesin loss eliminates all loop domains. Cell. 2017;171:305\u201320.e24. https:\/\/doi.org\/10.1016\/j.cell.2017.09.026","journal-title":"Cell"},{"key":"3445_CR52","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1038\/s41588-022-01223-8","volume":"54","author":"THS Hsieh","year":"2022","unstructured":"Hsieh THS, et al. Enhancer-promoter interactions and transcription are largely maintained upon acute loss of CTCF, cohesin, WAPL or YY1. Nat Genet. 2022;54:1919\u201332. https:\/\/doi.org\/10.1038\/s41588-022-01223-8.","journal-title":"Nat Genet"},{"key":"3445_CR53","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1002\/ijc.35378","volume":"158","author":"AD Swett","year":"2026","unstructured":"Swett AD, Tothova Z. Cohesin mutations and chromatin changes in cancer. Int J Cancer. 2026;158:368\u201381. https:\/\/doi.org\/10.1002\/ijc.35378.","journal-title":"Int J Cancer"},{"key":"3445_CR54","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1038\/s41588-025-02358-0","volume":"57","author":"R Han","year":"2025","unstructured":"Han R, et al. Characterization of induced cohesin loop extrusion trajectories in living cells. Nat Genet. 2025;57:2785\u201397. https:\/\/doi.org\/10.1038\/s41588-025-02358-0.","journal-title":"Nat Genet"},{"key":"3445_CR55","doi-asserted-by":"publisher","first-page":"eadt4221","DOI":"10.1126\/science.adt4221","volume":"391","author":"KL Hansen","year":"2025","unstructured":"Hansen KL, et al. Synergy between regulatory elements can render cohesin dispensable for distal enhancer function. Science. 2025;391:eadt4221. https:\/\/doi.org\/10.1126\/science.adt4221.","journal-title":"Science"},{"key":"3445_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41388-024-03174-2","volume":"44","author":"ST Jakobsen","year":"2025","unstructured":"Jakobsen ST, Siersbaek R. Transcriptional regulation by MYC: an emerging new model. Oncogene. 2025;44:1\u20137. https:\/\/doi.org\/10.1038\/s41388-024-03174-2.","journal-title":"Oncogene"},{"key":"3445_CR57","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.cell.2016.12.013","volume":"168","author":"JE Bradner","year":"2017","unstructured":"Bradner JE, et al. Transcriptional addiction in cancer. Cell. 2017;168:629\u201343. https:\/\/doi.org\/10.1016\/j.cell.2016.12.013.","journal-title":"Cell"},{"key":"3445_CR58","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/s41591-024-02805-1","volume":"30","author":"E Garralda","year":"2024","unstructured":"Garralda E, et al. MYC targeting by OMO-103 in solid tumors: a phase 1 trial. Nat Med. 2024;30:762\u201371. https:\/\/doi.org\/10.1038\/s41591-024-02805-1.","journal-title":"Nat Med"},{"key":"3445_CR59","doi-asserted-by":"publisher","first-page":"102957","DOI":"10.1016\/j.ctrv.2025.102957","volume":"137","author":"MJ Duffy","year":"2025","unstructured":"Duffy MJ, et al. MYC as a target for cancer treatment: from undruggable to druggable. Cancer Treat Rev. 2025;137:102957. https:\/\/doi.org\/10.1016\/j.ctrv.2025.102957.","journal-title":"Cancer Treat Rev"},{"key":"3445_CR60","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1016\/j.cell.2017.11.009","volume":"171","author":"AC Palmer","year":"2017","unstructured":"Palmer AC, Sorger PK. Combination cancer therapy can confer benefit via patient-to-patient variability without drug additivity or synergy. Cell. 2017;171:1678\u20131691.e13. https:\/\/doi.org\/10.1016\/j.cell.2017.11.009","journal-title":"Cell"},{"key":"3445_CR61","doi-asserted-by":"publisher","first-page":"104846","DOI":"10.1016\/j.ebiom.2023.104846","volume":"97","author":"S Lin","year":"2023","unstructured":"Lin S, et al. Single-nucleus RNA sequencing reveals heterogeneous microenvironments and specific drug response between cervical squamous cell carcinoma and adenocarcinoma. EBioMedicine. 2023;97:104846. https:\/\/doi.org\/10.1016\/j.ebiom.2023.104846.","journal-title":"EBioMedicine"},{"key":"3445_CR62","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41698-025-00948-z","volume":"9","author":"P Xia","year":"2025","unstructured":"Xia P, et al. Deciphering the cellular and molecular landscape of cervical cancer progression through single-cell and spatial transcriptomics. NPJ Precis Oncol. 2025;9:158. https:\/\/doi.org\/10.1038\/s41698-025-00948-z.","journal-title":"NPJ Precis Oncol"},{"key":"3445_CR63","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.molcel.2019.05.003","volume":"75","author":"ML Suva","year":"2019","unstructured":"Suva ML, Tirosh I. Single-cell RNA sequencing in cancer: lessons learned and emerging challenges. Mol Cell. 2019;75:7\u201312. https:\/\/doi.org\/10.1016\/j.molcel.2019.05.003.","journal-title":"Mol Cell"},{"key":"3445_CR64","doi-asserted-by":"publisher","first-page":"5809","DOI":"10.1038\/s41467-024-49965-9","volume":"15","author":"MR Patterson","year":"2024","unstructured":"Patterson MR, et al. The Hippo pathway transcription factors YAP and TAZ play HPV-type dependent roles in cervical cancer. Nat Commun. 2024;15:5809. https:\/\/doi.org\/10.1038\/s41467-024-49965-9.","journal-title":"Nat Commun"},{"key":"3445_CR65","doi-asserted-by":"publisher","first-page":"1703032","DOI":"10.3389\/fimmu.2025.1703032","volume":"16","author":"A Guo","year":"2025","unstructured":"Guo A, et al. Multi-omics reveals that NOTCH1 promotes cervical cancer progression and reduces radiosensitivity. Front Immunol. 2025;16:1703032. https:\/\/doi.org\/10.3389\/fimmu.2025.1703032.","journal-title":"Front Immunol"},{"key":"3445_CR66","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.cell.2017.04.001","volume":"169","author":"BD Manning","year":"2017","unstructured":"Manning BD, Toker A. AKT\/PKB signaling: navigating the network. Cell. 2017;169:381\u2013405. https:\/\/doi.org\/10.1016\/j.cell.2017.04.001.","journal-title":"Cell"},{"key":"3445_CR67","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/s41580-020-0255-7","volume":"21","author":"H Lavoie","year":"2020","unstructured":"Lavoie H, et al. ERK signalling: a master regulator of cell behaviour, life and fate. Nat Rev Mol Cell Biol. 2020;21:607\u201332. https:\/\/doi.org\/10.1038\/s41580-020-0255-7.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3445_CR68","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3892\/ol.2025.15375","volume":"31","author":"X Zhou","year":"2026","unstructured":"Zhou X, et al. Cervical cancer immune microenvironment: mechanisms of HPV-mediated immune evasion and advances in immunotherapy (Review). Oncol Lett. 2026;31:22. https:\/\/doi.org\/10.3892\/ol.2025.15375.","journal-title":"Oncol Lett"},{"key":"3445_CR69","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.14670\/HH-18-727","volume":"39","author":"M Mastrogeorgiou","year":"2024","unstructured":"Mastrogeorgiou M, et al. The immune microenvironment of cancer of the uterine cervix. Histol Histopathol. 2024;39:1245\u201371. https:\/\/doi.org\/10.14670\/HH-18-727.","journal-title":"Histol Histopathol"},{"key":"3445_CR70","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nature21349","volume":"541","author":"DS Chen","year":"2017","unstructured":"Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541:321\u201330. https:\/\/doi.org\/10.1038\/nature21349.","journal-title":"Nature"},{"key":"3445_CR71","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","volume":"24","author":"M Binnewies","year":"2018","unstructured":"Binnewies M, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24:541\u201350. https:\/\/doi.org\/10.1038\/s41591-018-0014-x.","journal-title":"Nat Med"},{"key":"3445_CR72","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s13046-025-03432-5","volume":"44","author":"Z Lin","year":"2025","unstructured":"Lin Z, et al. Deciphering the tumor immune microenvironment: single-cell and spatial transcriptomic insights into cervical cancer fibroblasts. J Exp Clin Cancer Res. 2025;44:194. https:\/\/doi.org\/10.1186\/s13046-025-03432-5.","journal-title":"J Exp Clin Cancer Res"},{"key":"3445_CR73","doi-asserted-by":"publisher","first-page":"20467","DOI":"10.1038\/s41598-025-05435-w","volume":"15","author":"Q Hu","year":"2025","unstructured":"Hu Q, et al. CXCL8 is essential for cervical cancer cell acquired radioresistance and acts as a promising therapeutic target in cervical cancer. Sci Rep. 2025;15:20467. https:\/\/doi.org\/10.1038\/s41598-025-05435-w.","journal-title":"Sci Rep"},{"key":"3445_CR74","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.tips.2021.11.004","volume":"43","author":"C Nogales","year":"2022","unstructured":"Nogales C, et al. Network pharmacology: curing causal mechanisms instead of treating symptoms. Trends Pharmacol Sci. 2022;43:136\u201350. https:\/\/doi.org\/10.1016\/j.tips.2021.11.004.","journal-title":"Trends Pharmacol Sci"},{"key":"3445_CR75","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s12672-026-04588-y","volume":"17","author":"H Shi","year":"2026","unstructured":"Shi H, et al. Precision management of cervical cancer emphasizes immunotherapy combination regimens and translational advances. Discov Oncol. 2026;17:435. https:\/\/doi.org\/10.1007\/s12672-026-04588-y.","journal-title":"Discov Oncol"},{"key":"3445_CR76","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s41236-017-0005-8","volume":"1","author":"JGT Za\u00f1udo","year":"2017","unstructured":"Za\u00f1udo JGT, et al. A network modeling approach to elucidate drug resistance mechanisms and predict combinatorial drug treatments in breast cancer. Cancer Converg. 2017;1:5. https:\/\/doi.org\/10.1186\/s41236-017-0005-8.","journal-title":"Cancer Converg"},{"key":"3445_CR77","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/nmeth.4225","volume":"14","author":"JP Shen","year":"2017","unstructured":"Shen JP, et al. Combinatorial CRISPR-Cas9 screens for de novo mapping of genetic interactions. Nat Methods. 2017;14:573\u20136. https:\/\/doi.org\/10.1038\/nmeth.4225.","journal-title":"Nat Methods"},{"key":"3445_CR78","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41573-019-0046-z","volume":"19","author":"A Huang","year":"2020","unstructured":"Huang A, et al. Synthetic lethality as an engine for cancer drug target discovery. Nat Rev Drug Discov. 2020;19:23\u201338. https:\/\/doi.org\/10.1038\/s41573-019-0046-z.","journal-title":"Nat Rev Drug Discov"},{"key":"3445_CR79","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1038\/s41591-022-01981-2","volume":"28","author":"JN Acosta","year":"2022","unstructured":"Acosta JN, et al. Multimodal biomedical AI. Nat Med. 2022;28:1773\u201384. https:\/\/doi.org\/10.1038\/s41591-022-01981-2.","journal-title":"Nat Med"},{"key":"3445_CR80","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/j.ccell.2022.09.012","volume":"40","author":"J Lipkova","year":"2022","unstructured":"Lipkova J, et al. Artificial intelligence for multimodal data integration in oncology. Cancer Cell. 2022;40:1095\u2013110. https:\/\/doi.org\/10.1016\/j.ccell.2022.09.012.","journal-title":"Cancer Cell"},{"key":"3445_CR81","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1038\/s41586-022-05688-9","volume":"614","author":"K Kamimoto","year":"2023","unstructured":"Kamimoto K, et al. Dissecting cell identity via network inference and in silico gene perturbation. Nature. 2023;614:742\u201351. https:\/\/doi.org\/10.1038\/s41586-022-05688-9.","journal-title":"Nature"},{"key":"3445_CR82","doi-asserted-by":"publisher","first-page":"e11517","DOI":"10.15252\/msb.202211517","volume":"19","author":"M Lotfollahi","year":"2023","unstructured":"Lotfollahi M, et al. Predicting cellular responses to complex perturbations in high-throughput screens. Mol Syst Biol. 2023;19:e11517. https:\/\/doi.org\/10.15252\/msb.202211517.","journal-title":"Mol Syst Biol"},{"key":"3445_CR83","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1016\/j.cell.2025.02.012","volume":"188","author":"L Binan","year":"2025","unstructured":"Binan L, et al. Simultaneous CRISPR screening and spatial transcriptomics reveal intracellular, intercellular, and functional transcriptional circuits. Cell. 2025;188:2141\u201358.e18. https:\/\/doi.org\/10.1016\/j.cell.2025.02.012","journal-title":"Cell"},{"key":"3445_CR84","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/nrg3899","volume":"16","author":"O Shalem","year":"2015","unstructured":"Shalem O, et al. High-throughput functional genomics using CRISPR-Cas9. Nat Rev Genet. 2015;16:299\u2013311. https:\/\/doi.org\/10.1038\/nrg3899.","journal-title":"Nat Rev Genet"},{"key":"3445_CR85","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1016\/j.cell.2016.11.048","volume":"167","author":"B Adamson","year":"2016","unstructured":"Adamson B, et al. A multiplexed single-cell CRISPR screening platform enables systematic dissection of the unfolded protein response. Cell. 2016;167:1867\u20131882.e21. https:\/\/doi.org\/10.1016\/j.cell.2016.11.048","journal-title":"Cell"},{"key":"3445_CR86","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.cell.2018.11.029","volume":"176","author":"M Gasperini","year":"2019","unstructured":"Gasperini M, et al. A genome-wide framework for mapping gene regulation via cellular genetic screens. Cell. 2019;176:377\u201390.e19. https:\/\/doi.org\/10.1016\/j.cell.2018.11.029","journal-title":"Cell"},{"key":"3445_CR87","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1038\/s41592-023-02040-5","volume":"20","author":"M Dong","year":"2023","unstructured":"Dong M, et al. Causal identification of single-cell experimental perturbation effects with CINEMA-OT. Nat Methods. 2023;20:1769\u201379. https:\/\/doi.org\/10.1038\/s41592-023-02040-5.","journal-title":"Nat Methods"},{"key":"3445_CR88","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/s41586-024-07663-y","volume":"632","author":"PF Renz","year":"2024","unstructured":"Renz PF, et al. In vivo single-cell CRISPR uncovers distinct TNF programmes in tumour evolution. Nature. 2024;632:419\u201328. https:\/\/doi.org\/10.1038\/s41586-024-07663-y.","journal-title":"Nature"},{"key":"3445_CR89","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/s41551-025-01437-1","volume":"10","author":"M Breinig","year":"2026","unstructured":"Breinig M, et al. Integrated in vivo combinatorial functional genomics and spatial transcriptomics of tumours to decode genotype-to-phenotype relationships. Nat Biomed Eng. 2026;10:125\u201343. https:\/\/doi.org\/10.1038\/s41551-025-01437-1.","journal-title":"Nat Biomed Eng"},{"key":"3445_CR90","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1186\/s13059-024-03404-6","volume":"25","author":"SJ Liu","year":"2024","unstructured":"Liu SJ, et al. In vivo perturb-seq of cancer and microenvironment cells dissects oncologic drivers and radiotherapy responses in glioblastoma. Genome Biol. 2024;25:256. https:\/\/doi.org\/10.1186\/s13059-024-03404-6.","journal-title":"Genome Biol"},{"key":"3445_CR91","doi-asserted-by":"publisher","first-page":"100940","DOI":"10.1016\/j.landig.2025.100940","volume":"7","author":"AG Rockall","year":"2025","unstructured":"Rockall AG, et al. Artificial intelligence in women\u2019s cancers: innovation and challenges in clinical translation. Lancet Digit Health. 2025;7:100940. https:\/\/doi.org\/10.1016\/j.landig.2025.100940.","journal-title":"Lancet Digit Health"},{"key":"3445_CR92","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/s43018-025-00917-2","volume":"6","author":"TG Chang","year":"2025","unstructured":"Chang TG, et al. Hallmarks of artificial intelligence contributions to precision oncology. Nat Cancer. 2025;6:417\u201331. https:\/\/doi.org\/10.1038\/s43018-025-00917-2.","journal-title":"Nat Cancer"},{"key":"3445_CR93","doi-asserted-by":"publisher","first-page":"e8664","DOI":"10.15252\/msb.20188664","volume":"16","author":"F Eduati","year":"2020","unstructured":"Eduati F, et al. Patient-specific logic models of signaling pathways from screenings on cancer biopsies to prioritize personalized combination therapies. Mol Syst Biol. 2020;16:e8664. https:\/\/doi.org\/10.15252\/msb.20188664.","journal-title":"Mol Syst Biol"},{"key":"3445_CR94","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.ymeth.2020.01.011","volume":"185","author":"M Viceconti","year":"2021","unstructured":"Viceconti M, et al. In silico trials: verification, validation and uncertainty quantification of predictive models used in the regulatory evaluation of biomedical products. Methods. 2021;185:120\u20137. https:\/\/doi.org\/10.1016\/j.ymeth.2020.01.011.","journal-title":"Methods"},{"key":"3445_CR95","doi-asserted-by":"publisher","first-page":"2078628","DOI":"10.1080\/23723556.2022.2078628","volume":"9","author":"ML Zu\u00f1iga Martinez","year":"2022","unstructured":"Zu\u00f1iga Martinez ML, et al. Establishment, authenticity, and characterization of cervical cancer cell lines. Mol Cell Oncol. 2022;9:2078628. https:\/\/doi.org\/10.1080\/23723556.2022.2078628.","journal-title":"Mol Cell Oncol"},{"key":"3445_CR96","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/s12864-024-10101-y","volume":"25","author":"Z Wang","year":"2024","unstructured":"Wang Z, et al. Long-read sequencing reveals the structural complexity of genomic integration of HPV DNA in cervical cancer cell lines. BMC Genomics. 2024;25:198. https:\/\/doi.org\/10.1186\/s12864-024-10101-y.","journal-title":"BMC Genomics"},{"key":"3445_CR97","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/j.stem.2021.03.012","volume":"28","author":"K Lohmussaar","year":"2021","unstructured":"Lohmussaar K, et al. Patient-derived organoids model cervical tissue dynamics and viral oncogenesis in cervical cancer. Cell Stem Cell. 2021;28:1380\u20131396.e6. https:\/\/doi.org\/10.1016\/j.stem.2021.03.012","journal-title":"Cell Stem Cell"},{"key":"3445_CR98","doi-asserted-by":"publisher","first-page":"e35","DOI":"10.3802\/jgo.2023.34.e35","volume":"34","author":"HS Seol","year":"2023","unstructured":"Seol HS, et al. Preclinical investigation of patient-derived cervical cancer organoids for precision medicine. J Gynecol Oncol. 2023;34:e35. https:\/\/doi.org\/10.3802\/jgo.2023.34.e35.","journal-title":"J Gynecol Oncol"},{"key":"3445_CR99","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.62347\/FNTD1712","volume":"15","author":"H Ye","year":"2025","unstructured":"Ye H, et al. Organoid technology in cervical cancer research. Am J Cancer Res. 2025;15:1988\u20132003. https:\/\/doi.org\/10.62347\/FNTD1712.","journal-title":"Am J Cancer Res"},{"key":"3445_CR100","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/s41568-018-0007-6","volume":"18","author":"J Drost","year":"2018","unstructured":"Drost J, Clevers H. Organoids in cancer research. Nat Rev Cancer. 2018;18:407\u201318. https:\/\/doi.org\/10.1038\/s41568-018-0007-6.","journal-title":"Nat Rev Cancer"},{"key":"3445_CR101","doi-asserted-by":"publisher","first-page":"5376","DOI":"10.1158\/1078-0432.CCR-18-3590","volume":"25","author":"CA Pasch","year":"2019","unstructured":"Pasch CA, et al. Patient-derived cancer organoid cultures to predict sensitivity to chemotherapy and radiation. Clin Cancer Res. 2019;25:5376\u201387. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-3590.","journal-title":"Clin Cancer Res"},{"key":"3445_CR102","doi-asserted-by":"publisher","first-page":"100621","DOI":"10.1016\/j.jgeb.2025.100621","volume":"23","author":"K Kumagai","year":"2025","unstructured":"Kumagai K, et al. Design biology and mind-body health. J Genet Eng Biotechnol. 2025;23:100621. https:\/\/doi.org\/10.1016\/j.jgeb.2025.100621.","journal-title":"J Genet Eng Biotechnol"},{"key":"3445_CR103","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s13059-023-02926-9","volume":"24","author":"M Karimzadeh","year":"2023","unstructured":"Karimzadeh M, et al. Human papillomavirus integration transforms chromatin to drive oncogenesis. Genome Biol. 2023;24:142. https:\/\/doi.org\/10.1186\/s13059-023-02926-9.","journal-title":"Genome Biol"},{"key":"3445_CR104","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1002\/ijc.31986","volume":"144","author":"O Rataj","year":"2019","unstructured":"Rataj O, et al. Brd4 inhibition suppresses HPV16 E6 expression and enhances chemoresponse: a potential new target in cervical cancer therapy. Int J Cancer. 2019;144:2330\u20138. https:\/\/doi.org\/10.1002\/ijc.31986.","journal-title":"Int J Cancer"},{"key":"3445_CR105","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.1038\/s41388-021-01735-3","volume":"40","author":"M Ni","year":"2021","unstructured":"Ni M, et al. BRD4 inhibition sensitizes cervical cancer to radiotherapy by attenuating DNA repair. Oncogene. 2021;40:2711\u201324. https:\/\/doi.org\/10.1038\/s41388-021-01735-3.","journal-title":"Oncogene"},{"key":"3445_CR106","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1016\/j.humpath.2012.11.007","volume":"44","author":"H Cho","year":"2013","unstructured":"Cho H, et al. Loss of ARID1A\/BAF250a expression is linked to tumor progression and adverse prognosis in cervical cancer. Hum Pathol. 2013;44:1365\u201374. https:\/\/doi.org\/10.1016\/j.humpath.2012.11.007.","journal-title":"Hum Pathol"},{"key":"3445_CR107","doi-asserted-by":"publisher","first-page":"oyaf133","DOI":"10.1093\/oncolo\/oyaf133","volume":"30","author":"C Zhu","year":"2025","unstructured":"Zhu C, et al. Predictive role of ARID1A and B2M mutations and the antigen presentation pathway in the efficacy of definitive chemoradiotherapy for cervical cancer. Oncologist. 2025;30:oyaf133. https:\/\/doi.org\/10.1093\/oncolo\/oyaf133.","journal-title":"Oncologist"},{"key":"3445_CR108","doi-asserted-by":"publisher","first-page":"10999","DOI":"10.1128\/JVI.00160-11","volume":"85","author":"PL Hyland","year":"2011","unstructured":"Hyland PL, et al. Evidence for alteration of EZH2, BMI1, and KDM6A and epigenetic reprogramming in human papillomavirus type 16 E6\/E7-expressing keratinocytes. J Virol. 2011;85:10999\u20131006. https:\/\/doi.org\/10.1128\/JVI.00160-11.","journal-title":"J Virol"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03445-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-026-03445-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03445-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T11:45:45Z","timestamp":1791459945000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-026-03445-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,8]]},"references-count":108,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,11]]}},"alternative-id":["3445"],"URL":"https:\/\/doi.org\/10.1007\/s12032-026-03445-w","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,8]]},"assertion":[{"value":"26 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is a review and does not report new studies involving human participants, human tissue, animals, or clinical samples performed by the authors. Therefore, ethics approval was not required.","order":3,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This article is a review and does not report a clinical trial conducted by the authors.","order":5,"name":"Ethics","label":"Clinical trial registration","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"324"}}